Timothy Chole - Apr 1, 2025 Form 4 Insider Report for ROCKWELL MEDICAL, INC. (RMTI)

Role: SVP, Chief Commercial Officer
Signature: /s/ Megan Timmins, Attorney-in-Fact for Timothy Chole
Stock symbol: RMTI
Transactions as of: Apr 1, 2025
Transactions value $: -$3,097
Form type: 4
Date filed: 4/2/2025, 06:03 PM
Previous filing: Mar 18, 2025
Next filing: May 21, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RMTI	Common Stock	Sale	-$3.1K	-2.87K	-5.86%	$1.08	46K	Apr 1, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024 in multiple trades at prices ranging from $1.065 to $1.095. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Content

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024 in multiple trades at prices ranging from $1.065 to $1.095. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.